Impact of 5-HT 3 receptor antagonists on chemotherapy-induced nausea and vomiting: A retrospective cohort study

BMC Health Services Research

Volumn 12, Issue 1, 2012, Pages

  Lin, Swu Jane ^a,b   Hatoum, Hind T ^a,b   Buchner, Deborah ^c   Cox, David ^c   Balu, Sanjeev ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Hind T Hatoum and Company   (United States)

^c EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ISOQUINOLINE DERIVATIVE; PALONOSETRON; QUINUCLIDINE DERIVATIVE; SEROTONIN 3 ANTAGONIST;

ADULT; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; FEMALE; HEALTH CARE SURVEY; HOSPITALIZATION; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; NAUSEA; RETROSPECTIVE STUDY; STATISTICAL MODEL; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARBOPLATIN; CISPLATIN; FEMALE; HEALTH CARE SURVEYS; HOSPITALIZATION; HUMANS; ISOQUINOLINES; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; QUINUCLIDINES; RETROSPECTIVE STUDIES; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; VOMITING;

EID: 84866120211     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-12-215     Document Type: Article

References (21)

1. Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM, Lindenauer PK, J Clin Oncol 2003 21 7 1373 1378 10.1200/JCO.2003.08.118 12663729
2. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, et al. Ann Oncol 2006 17 9 1441 1449 10.1093/annonc/mdl137 16766588
3. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting. Oo TH, Hesketh PJ, Nat Clin Pract Oncol 2005 2 4 196 201 10.1038/ncponc0132 16264934
4. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. Rojas C, Li Y, Zhang J, Stathis M, Alt J, Thomas AG, Cantoreggi S, Sebastiani S, Pietra C, Slusher BS, The Journal of pharmacology and experimental therapeutics 2010 335 2 362 368 10.1124/jpet.110.166181 20724484
5. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB, Sebastiani S, Cantoreggi S, Slusher BS, Eur J Pharmacol 2010 626 2-3 193 199 19836386
6. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S, Cancer 2003 98 11 2473 2482 10.1002/cncr.11817 14635083
7. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M, Ann Oncol 2003 14 10 1570 1577 10.1093/annonc/mdg417 14504060
8. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S, Lancet Oncol 2009 10 2 115 124 10.1016/S1470-2045(08)70313-9 19135415
9. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein E, Sebastiani S, Cantoreggi S, Snyder SH, et al. Anesth Analg 2008 107 2 469 478 10.1213/ane.0b013e318172fa74 18633025
10. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system. Dunn JD, Cannon E, Mitchell MP, Curtiss FR, J Manag Care Pharm 2006 12 4 294 302 16792435
11. The effects of antihypertensive step-therapy protocols on pharmaceutical and medical utilization and expenditures. Mark TL, Gibson TB, McGuigan KA, Am J Manag Care 2009 15 2 123 131 19284809
12. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders. Panzer PE, Regan TS, Chiao E, Sarnes MW, Am J Manag Care 2005 11 12 Suppl 370 379 16236019
13. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy. Yokoyama K, Yang W, Preblick R, Frech-Tamas F, J Manag Care Pharm 2007 13 3 235 244 17407390
14. About AMCP, http://www.amcp.org/InformationForSec.aspx?id=8821, accessed June 24, 2012
15. Effect of 6 managed care pharmacy tools: a review of the literature. Abt asssociates, J Manag Care Pharm 2009 16 6-a 3 S20
16. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. Jick SS, Hernandez RK, BMJ 2011 342 2151 10.1136/bmj.d2151 21511805
17. Antiemesis. Clinical Practice Guidelines in Oncology. Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, et al. J Natl Compr Canc Netw 2009 7 5 572 595 19460282
18. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Charlson ME, Pompei P, Ales KL, MacKenzie CR, J Chronic Dis 1987 40 5 373 383 10.1016/0021-9681(87)90171-8 3558716
19. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA, Med Care 2005 43 11 1130 1139 10.1097/01.mlr.0000182534.19832.83 16224307
20. Yeh YC, McDonnell A, Klinger EV, Fowler B, Matta L, Voit D Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract, Reddy P 2010
21. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? Hamadani M, Chaudhary L, Awan FT, Khan JK, Kojouri K, Ozer H, Tfayli A, J Oncol Pharm Pract 2007 13 2 69 75 10.1177/1078155207078137 17873106